Candel Therapeutics (CADL) Income from Continuing Operations (2020 - 2025)
Candel Therapeutics (CADL) reported Income from Continuing Operations of 15227000.0 for Q4 2025, down 91.63% on a YoY basis from 181945476.69 in Q4 2024, and up 35.61% sequentially from 23649000.0 in Q3 2025.
Candel Therapeutics (CADL) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 6 years of Income from Continuing Operations data on file, last reported at 15227000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 91.63% year-over-year to 15227000.0; the trailing twelve-month figure through Dec 2025 stood at 81447000.0 (down 15.18% YoY), and the FY2025 full-year result was 109619000.0, down 83.05% from the prior year.
- Income from Continuing Operations rose to 15227000.0 in Q4 2025, from 23649000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4669000.0 in Q1 2021 to a low of 38152000.0 in Q1 2022.
- A 5-year average of 15537250.0 and a median of 10344500.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 717.13% in 2022 and jumped 73.19% in 2023, its largest moves.
- Tracing CADL's Income from Continuing Operations over 5 years: stood at 26084000.0 in 2021, then soared by 67.34% to 8519000.0 in 2022, then fell by 22.77% to 10459000.0 in 2023, then climbed by 24.03% to 7946000.0 in 2024, then tumbled by 91.63% to 15227000.0 in 2025.
- Business Quant data shows CADL's Income from Continuing Operations at 15227000.0 in Q4 2025, 23649000.0 in Q3 2025, and 21524000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Candel Therapeutics | 504.70 Mn | 504.70 Mn | - | -15.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.23 Mn |
| Sep 30, 2025 | -23.65 Mn |
| Jun 30, 2025 | -21.52 Mn |
| Mar 31, 2025 | -21.05 Mn |
| Dec 31, 2024 | -7.95 Mn |
| Sep 30, 2024 | -28.82 Mn |
| Jun 30, 2024 | -25.72 Mn |
| Mar 31, 2024 | -8.23 Mn |
| Dec 31, 2023 | -10.46 Mn |
| Sep 30, 2023 | -9.52 Mn |
| Jun 30, 2023 | -19.57 Mn |
| Mar 31, 2023 | -10.23 Mn |
| Dec 31, 2022 | -8.52 Mn |
| Sep 30, 2022 | -9.06 Mn |
| Jun 30, 2022 | -9.12 Mn |
| Mar 31, 2022 | -38.15 Mn |
| Dec 31, 2021 | -26.08 Mn |
| Sep 30, 2021 | -7.90 Mn |
| Jun 30, 2021 | -5.32 Mn |
| Mar 31, 2021 | -4.67 Mn |